BioCentury
ARTICLE | Company News

China's Everest gets rights to Novartis' FGFR4 inhibitor

June 29, 2018 5:25 PM UTC

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) gained an exclusive, worldwide license to FGF401 from Novartis AG (NYSE:NVS; SIX:NOVN). The deal marks the second in-licensing of a fibroblast growth factor (FGF) receptor 4 (FGFR4; CD334) inhibitor by a Chinese company in June.

FGF401 is in Phase I/II testing in the U.S., Europe and Asia to treat hepatocellular carcinoma (HCC) and other solid tumors that are positive for FGFR4 and klotho beta (KLB). Everest declined to disclose financial terms...